-
Your selected country is
Luxembourg
- Change country/language
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.
The CD55 antibody, clone IA10, is derived from the fusion of X63Ag8.653 myeloma cells with spleen cells from BALB/c mice immunized with purified DAF. The CD55 antibody reacts with decay-accelerating factor (DAF), a GPI-anchored single chain glycoprotein of approximately 70 kilodaltons (kDa). It has been suggested that the role of DAF is to protect cells from damage by autologous complement preventing the amplification steps of the complement cascade by interfering with the assembly of the C3 and the C5 convertases. The complement components in the formation of C3 convertases include: C4b2a (classical pathway) and C3bBb (alternative pathway). In the formation of C5 convertases, the complement components include: C4b2a3b (classical pathway) and C3bBb3b (alternative pathway).
Development References (8)
-
Bessler M, Mason PJ, Hillmen P, et al. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J. 1994; 13:110-117. (Biology).
-
Brodbeck WG, Kuttner-Kondo L, Mold C, Medof ME. Structure/function studies of human decay-accelerating factor. Immunology. 2000; 101:104-111. (Biology).
-
Centers for Disease Control. Perspectives in disease prevention and health promotion update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR. 1988; 37:377-388. (Biology).
-
Clinical and Laboratory Standards Institute. 2005. (Biology).
-
Hall SE, Rosse WF. The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Blood. 1996; 87:5332-5340. (Biology).
-
Klickstein LB, Springer TA. Schlossman SF, Boumsell L, Gilks W, et al, ed. Leucocyte Typing V: White Cell Differentiation Antigens. New York, NY: 1995:1473-1474.
-
Kuby J. Immunology, ed. New York, NY: WH Freeman and Co; 1994:398-401.
-
Richards SJ, Rawstron AC, Hillmen P. Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry. 2000; 42:223-233. (Biology).
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
Although not required, these products are manufactured in accordance with Good Manufacturing Practices.